News about Market

FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer

The US FDA has cleared the OncoMate MSI Dx Analysis System as a companion diagnostic to guide pembrolizumab-based combination therapy in advanced endometrial cancer. The PCR-based assay determines microsatellite instability (MSI) status in tumour tissue, with support from Merck, developer of pembrolizumab and lenvatinib.

Market | 15/11/2025 | By Dineshwori |  311

Pfizer Cuts Majority of Its BioNTech Stake in Strategic Realignment

After the sale, Pfizer now holds around 1.66 million American Depositary Shares, valued at roughly USD 163 million as of late September 2025.

Market | 14/11/2025 | By Darshana |  248

Merck Poised to Acquire Cidara Therapeutics in Deal Valued Above USD 3.3 Billion

Merck & Co. is reportedly closing in on the acquisition of Cidara Therapeutics, a biotechnology company focused on long-acting antibody treatments for influenza. The deal is expected to value Cidara above its USD 3.3 billion market capitalisation.

Market | 14/11/2025 | By Darshana |  142

Natural Capsules Posts Stable Q2, but US Tariffs Slow HPMC Expansion

Natural Capsules, one of India’s leading capsule manufacturers, has announced its financial results for the quarter and half year ended September 30, 2025, reporting steady demand but acknowledging multiple external and operational challenges that have impacted growth.

Market | 14/11/2025 | By Dineshwori |  287

Lupin Receives EIR from US FDA for its Aurangabad (CSN) Facility

Lupin has received an Establishment Inspection Report (EIR) from the US FDA for its Aurangabad (CSN) facility, marking the successful closure of a product-specific Pre-Approval Inspection conducted between September 1 and September 5, 2025.

Market | 14/11/2025 | By Dineshwori |  206

JB Pharma Q2 FY26 Net Profit Rises 19 Percent to INR 208 Crore

JB Chemicals & Pharmaceuticals reported a net profit of INR 208 crore for the quarter ended September 30, 2025, marking a 19 percent year-on-year increase from INR 175 crore in the same period last year.

Market | 12/11/2025 | By Darshana |  169

GENFIT and EVerZom Partner to Advance Exosome-based Regenerative Technology in ACLF

Under the collaboration, GENFIT and EVerZom will combine expertise to advance EViv, an exosome-based regenerative therapy for ACLF, with GENFIT leading preclinical evaluation and EVerZom providing its bioproduction platform. GENFIT also holds an exclusive option to licence the programme following successful proof-of-concept results.

Market | 12/11/2025 | By Dineshwori |  195

Glenmark Secures China's Approval For RYALTRIS

Glenmark Pharmaceuticals has received regulatory approval in China for RYALTRIS. Combining olopatadine hydrochloride and mometasone furoate, it offers dual-action relief from nasal symptoms, further strengthening Glenmark’s position as a global leader in respiratory innovation.

Market | 11/11/2025 | By Dineshwori |  417

FDA Approves DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma

The US FDA has approved DARZALEX Faspro as the first treatment for adult patients with High-Risk Smoldering Multiple Myeloma (HR-SMM), marking a key milestone in addressing this early stage of the disease.

Market | 11/11/2025 | By Dineshwori |  177

Organon Announces Agreement to Divest its JADA System for up to USD 465 Million to Laborie

Organon has entered into a definitive agreement to divest its JADA System to Laborie for up to USD 465 million. The deal aims to leverage Laborie’s expertise in medical technology to expand the reach of JADA, enhancing access to postpartum hemorrhage treatment for mothers worldwide.

Market | 11/11/2025 | By Dineshwori |  310